Latest News and Press Releases

Arix Bioscience participates in $67 million Series C financing for Amplyx Pharmaceuticals  Series C financing to fund Phase II clinical trials of APX001, a novel antifungal agent to treat...

Arix Bioscience Half Yearly Report for the Six Months Ended 30 June 2017Transformative period with good progress across the business LONDON, 31 July 2017: Arix Bioscience plc (LSE:ARIX) ("Arix...

Arix Bioscience co-leads $29 million Series A financing for PreciThera, Inc. Funding to develop novel biologics targeting orphan bone diseases into clinical trials LONDON, 27 July 2017: Arix...

Arix Bioscience leads $45 million Series B financing round into LogicBio Therapeutics  Funding to advance gene therapies targeting orphan paediatric disorders through clinical trials LONDON,...

Arix Bioscience participates in $20 million fundraise for Mitoconix Bio Series A finance raised by high quality investor syndicate for neurodegenerative diseases therapies LONDON, 27 June,...

Arix Bioscience to present at Jefferies 2017 Global Healthcare Conference in New York LONDON, 31 May, 2017: Arix Bioscience plc (LSE: ARIX) ("Arix Bioscience" or "the Company"), a global...

Arix Bioscience co-leads $45 million Series B investment round for Harpoon Therapeutics - Funding to advance two of Harpoon's immuno-oncology programmes into clinical trials - LONDON, 25 May,...

Arix Bioscience leads $65 million Series B investment round for Iterum - Funding pivotal Phase 3 trial for novel antibiotic sulopenem- Investment in Ireland-based company focused on developing...